Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.

NCT07353268 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: QL1706 + Fruquintinib + Short-Course Ablative Radiotherapy (SCART)
DRUG: Standard Third-Line Therapy

Sponsor

Tao Zhang